Mohamed E M Saeed
Overview
Explore the profile of Mohamed E M Saeed including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
825
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saeed M, Cives-Losada C, Efferth T
Cancer Genomics Proteomics
. 2022 Oct;
19(6):727-739.
PMID: 36316038
Background/aim: Artemisinin and its derivatives are not only approved antimalarial drugs but also exert strong anticancer activity. Based on the clinical activity of artesunate (ART) that has been previously reported...
2.
Hai Y, Saeed M, Ponto K, Elflein H, Lee A, Fang S, et al.
Thyroid
. 2022 Sep;
32(12):1547-1558.
PMID: 36128805
Thyroid eye disease (TED) involves several pathogenic pathways and a battery of infiltrating mononuclear cells, cytokines, and chemokines in the orbit. Revealing the main molecules, which play a major role...
3.
Saeed M, Boulos J, Mucklich S, Leich E, Chatterjee M, Klauck S, et al.
Cancer Genomics Proteomics
. 2022 Aug;
19(5):540-555.
PMID: 35985681
Background/aim: Multiple myeloma (MM) is characterized by accumulation of a malignant clone of plasma cells in the bone marrow. Curative treatments are not yet available. Therefore, we undertook a drug...
4.
Lu X, Elbadawi M, Blatt S, Saeed M, Xiao X, Ma X, et al.
Chem Biol Interact
. 2022 Aug;
365:110062.
PMID: 35917945
Anti-angiogenesis targeting vascular endothelial growth factor receptor 2 (VEGFR2) has been considered an important strategy for cancer therapy. VEGFR2 inhibitors targeting tumor angiogenic pathways have been widely used in clinical...
5.
Saeed M, Drif A, Efferth T
Anticancer Res
. 2022 Jul;
42(7):3483-3494.
PMID: 35790273
Background/aim: Patients with metastatic tumors commonly have a poor prognosis. Frequently, patients suffering from progressive tumors have a high willingness for the compassionate use of non-approved medications. One of these...
6.
Saeed M, Boulos J, Machel K, Andabili N, Marouni T, Roth W, et al.
In Vivo
. 2022 Jun;
36(4):1651-1666.
PMID: 35738589
Background/aim: The ATP-binding cassette subfamily B member 5 (ABCB5) transporter plays a pivotal role in melanocyte progenitor cell fusion and has been identified as a tumor-initiating cell marker. In this...
7.
Saeed M, Khalid H, Thakur S, Efferth T
Cancer Genomics Proteomics
. 2022 Jun;
19(4):512-525.
PMID: 35732326
Background: Small cell vaginal carcinoma is a very rare gynecological cancer and treatments including chemo- and radiotherapy have had limited success. Case Report: We report the case of a 37-year-old...
8.
Yue G, Gomes A, Saeed M, Tsui K, Dawood M, Drif A, et al.
Phytomedicine
. 2022 May;
102:154183.
PMID: 35636176
Background: Esophageal cancer (EC) is highly prevalent in Eastern Asia (including China) with high rates of mortality. The metastatic tendency in EC is associated with a poor prognosis. Our previous...
9.
Saeed M, Yucer R, Dawood M, Hegazy M, Drif A, Ooko E, et al.
Int J Mol Sci
. 2022 Apr;
23(7).
PMID: 35409325
The improvement of cancer chemotherapy remains a major challenge, and thus new drugs are urgently required to develop new treatment regimes. Curcumin, a polyphenolic antioxidant derived from the rhizome of...
10.
Boulos J, Saeed M, Chatterjee M, Bulbul Y, Crudo F, Marko D, et al.
Pharmaceuticals (Basel)
. 2021 Nov;
14(11).
PMID: 34832908
Crizotinib was a first generation of ALK tyrosine kinase inhibitor approved for the treatment of -positive non-small-cell lung carcinoma (NSCLC) patients. COMPARE and cluster analyses of transcriptomic data of the...